Clinical trial / 2005
High-dose intravenous ascorbate was generally well tolerated in terminal cancer patients.
Twenty-four patients with late-stage terminal cancer received continuous intravenous ascorbate infusions ranging from 150 to 710 mg/kg/day for up to eight weeks. Infusions raised mean plasma ascorbate to 1.1 mM. Most adverse events were minor, such as nausea, edema, and dry mouth or skin. Two potentially related grade 3 events occurred: a kidney stone in a patient with a history of renal calculi and hypokalemia in another.
- Study type
- Uncontrolled clinical trial
- Who was studied
- 24 terminal cancer patients
- What was measured
- Safety, adverse events, plasma ascorbate, and disease progression
THE PAPER
A pilot clinical study of continuous intravenous ascorbate in terminal cancer patients.
Riordan HD, Casciari JJ, González MJ, Riordan NH, Miranda-Massari JR, Taylor P, Jackson JA. P R Health Sci J, 2005.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.